Johnson & Johnson is fast-forwarding its vaccine development program for COVID-19.
The healthcare company has selected a lead vaccine candidate and is planning to begin human trials in September, with first batches available under potential emergency use authorization in the first part of 2021.
The COVID-19 vaccine program is using Janssen's AdVac and PER.C6 technologies. These platforms can rapidly develop new vaccine candidates and accelerate the production of the optimal vaccine candidate.
The company has used the same platform for the manufacturing of its Ebola vaccine and construct its Zika, RSV, and HIV vaccine candidates who are in Phas...
